Search results
Showing 226 to 240 of 666 results for kidney or kidneys or renal
Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)
Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
congestion and worsening renal function, does the addition of low‑dose dopamine to standard therapy lead to greater diuresis and...
Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.
and publication of data on the outcomes of percutaneous cryotherapy for renal cancer in the long term is encouraged. Further research...
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.
All NICE products on renal stones. Includes any guidance, advice and quality standards.
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)
Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]
Awaiting development Reference number: GID-TA11886 Expected publication date: TBC
In development Reference number: GID-TA11352 Expected publication date: TBC
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.